REPLIMUNE GROUP INC stock forecast: down to 32.17 USD REPL stock price prognosis
Forecast for Tue 09 Nov 2021 price
REPLIMUNE GROUP INC stock price forecast for further price development down to -2.65% (time horizon: 1 day) and price target of 32.17 USD. Negative news sentiment. Short-term (time horizon: 2 weeks) REPLIMUNE GROUP INC share price prediction for 2021-11-09 with daily closed price projections
On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.
The forecast (dashed curve) of the share price performance is based on historical data.
Our forecast model is based on mathematical, statistical methods.
The website offers price forecasts and analysis tools for equities and other securities,
which are exclusively based on the prices of these securities in the past.
Information about these prices is provided to us by third parties. Although we believe,
If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and
correct sequencing of this information.
We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider
any financial data or other data of such issuers with the exception of the past prices of the securities.
Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or
that may be relevant for future security price flows. Investments require additional considerations.
Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor
or the tax implications an investment may have for the investor. Although we believe that
our mathematical models are a tool to try to explore the possibility for future price development
with the help of past performance, such developments are subject to a multitude of different influences.
and therefore not really predictable.
We cannot guarantee the success of any investment you make based on the information published here.
This website is for information purposes only. All information and data on this website cannot be guaranteed
to be accurate,
accuracy, completeness and appropriateness - neither explicit nor implicit.
Summerized Form 10-K with GPT-2
We expect the primary data read-out from this Phase 2 CERPASS trial in 2022. Initial data from this trial is expected to be presented in the second half of 2021. We expect the primary data readout from the CERPASS trial in 2022. We recently began dosing a patient in the non-small cell lung cancer cohort. We have also opened the ARTACUS trial for enrollment. We may rely, in some circumstances, on trade secrets to protect our technology. In most cases, the submission of a BLA is subject to a substantial application user fee. Certain payments for clinical trials are included within the ambit of this law. All of these conditions can affect realization and return on investment. The address of that website is https://www.sec.gov. We may not discover such a flaw until the clinical trial is at an advanced stage. Any such restrictions could limit sales of the product. We may never achieve or sustain profitability. Our operations have consumed substantial amounts of cash since inception. Such a license may not be available on commercially reasonable terms, or at all. Our stock price has been and is likely to be volatile.
Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.
Meta analyst score 53.87/100
Good financial position.
Historical view, profit is growing.
Company revenue is growing faster compared with the industry.
Stock price is above book price value.
Institutional ownership list is based on filling form information
REPLIMUNE GROUP INC Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.
On-Balance Volume information for REPLIMUNE GROUP INC. On-Balance Volume information can be an indicator for bullish or bearish outcome.
Accumulation / Distribution (A/D) indicator information for REPLIMUNE GROUP INC. The indicator identify divergences between price and volume flow.
Aroon Oscillator information for REPLIMUNE GROUP INC. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.
Average Directional Index (ADX) information for REPLIMUNE GROUP INC. The index can be used to identify the strengh of a trend.
Moving Average Convergence Divergence (MACD) for REPLIMUNE GROUP INC. The indicator helps to predict trend direction and the momentum of the trend.
Stochastic Oscillator as momentum indicator for REPLIMUNE GROUP INC. The indicator is useful for identifying overbought and oversold levels.
Relative Strength Index (RSI) for REPLIMUNE GROUP INC. RSI is a momentum oscillator that measures the speed and change of price development.
The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period.
Primary usage of the indicator is to identify overbought or oversold signals.
When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30
Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio